New Guideline for PSA Screening.

0
New Guideline for PSA Screening.

·

OverdOn November 12, 2026, the American Cancer Society announced new guidelines recommending regular prostate-specific antigen screening for defined groups of men. The change is significant. Its previous guidance emphasized an informed decision about whether to undergo screening; the new guidance affirmatively recommends testing, while retaining the requirement to explain its benefits and harms. The recommendation is more confident. The underlying science is stronger than it once was, but important uncertainties remain.

The recommended schedule is straightforward:

MenACS screening schedule
Average riskPSA every two years from ages 50 through 69
Black menAnnual PSA from ages 45 through 69
Non-Black men with a father, brother, or son diagnosed before 65, or multiple first-degree relatives diagnosed at any ageAnnual PSA from ages 45 through 69
Non-Black men with one first-degree relative diagnosed at 65 or olderPSA every two years from ages 45 through 69
Ages 70-74Individual decision; every two years if screening continues
Ages 75 and olderGenerally discontinue screening
Life expectancy under ten yearsDo not screen, regardless of age

Exceptionally healthy men aged 75-79 may discuss continuing, but screening is discouraged at 80 and beyond. Known inherited cancer predispositions require separate consideration. These recommendations concern men without symptoms or previously diagnosed prostate cancer.

The new guidance also emphasizes restraint after an abnormal result. An elevated PSA should ordinarily be repeated before further investigation. Persistent elevation should generally prompt MRI and/or a validated biomarker test to help decide whether biopsy is necessary. If a low-risk cancer is found, active surveillance should be offered initially. Screening is therefore conceived as a sequence of decisions, rather than a blood test followed automatically by biopsy and treatment.

The United States Preventive Services Task Force has not yet followed the ACS. Its current recommendation, issued in 2018, leaves screening at ages 55-69 to individual choice after discussion and recommends against screening at 70 or older. It does not establish a separate earlier screening schedule for Black men or men with a family history. Thus, the organizations differ over the strength of the recommendation, the starting age, and the stopping age.

The USPSTF recommendation is being revised. As of November 17, 2026, the task force has not announced a publication date for its revised recommendation. Its public update page lists a final research plan but no draft recommendation, so a reliable release estimate is not possible.

PSA screening has been emotionally charged throughout its clinical history. Finding cancer early has an immediate intuitive appeal. A man whose cancer was discovered through screening may understandably believe that the test saved his life. A physician who has watched a patient die of metastatic prostate cancer may find restraint difficult. Conversely, a man left incontinent or impotent after treatment for a cancer that might never have troubled him has an equally compelling experience.

Neither experience, however powerful, can establish the net benefit of screening a population. The individual usually cannot know what would have happened without testing. That missing alternative is precisely why randomized trials matter.

The ACS’s own history shows how recommendations preceded definitive evidence. In 1992 it recommended annual PSA testing beginning at 50. Its 1997 revision continued to offer annual testing while acknowledging that the observed reduction in prostate cancer mortality had not been established as a consequence of screening. The rationale relied substantially on detecting cancer at an earlier stage and the hope that this would increase cure rates.

That hope was reasonable, but it was not proof of reduced morbidity or mortality. Earlier diagnosis can lengthen survival measured from diagnosis without postponing death. Screening also preferentially discovers slowly growing disease, including cancers that would never become clinically important. Those effects can make a screening program look successful before it has demonstrated that patients live longer or suffer less.

Fairness requires acknowledging that the ACS subsequently became more cautious. Its 2010 guidance explicitly emphasized uncertainty and informed choice. The present recommendation therefore follows a period of restraint and the accumulation of longer-term evidence; it is not simply a continuation of its early enthusiasm.

The strongest new support comes from extended follow-up of randomized trials. In the European screening trial, prostate cancer mortality was reduced by 13% relatively over 23 years. The absolute reduction was 0.22 percentage points-about two fewer prostate cancer deaths per thousand men invited to screening. Approximately 456 men had to be invited to prevent one prostate cancer death. That is a meaningful result, but it is a modest benefit accumulated over a long time.

The demonstrated benefit concerns deaths attributed to prostate cancer. A clear reduction in overall mortality has not been established, although a small disease-specific benefit can be difficult to detect against the much larger number of deaths from other causes.

The British CAP trial also found a small reduction in prostate cancer mortality after a single screening invitation: approximately one fewer death per thousand men over 15 years. Evidence from the Rotterdam component of the European trial supports a reduction in metastatic disease. Avoiding metastases matters independently of survival because advanced cancer and its treatment impose considerable burdens.

These findings strengthen the case for selective screening. They do not establish that every earlier starting age or shorter interval is worthwhile. The evidence comparing annual with biennial screening is much weaker than the evidence comparing screening with usual care. Recommendations for higher-risk groups depend substantially on epidemiology, modeling, and expert judgment. Higher baseline risk makes greater absolute benefit plausible, but does not prove the optimal schedule. The ACS acknowledges these limitations.

Nor is screening necessarily benign. The needle used to obtain the blood is the least important hazard. An elevated result can lead to anxiety, repeat testing, imaging, and biopsy. Biopsy can cause bleeding, infection, pain, and urinary problems. A diagnosis can lead to surgery or radiation with lasting sexual, urinary, or bowel consequences. Overdiagnosis means discovering a genuine cancer that would never have caused symptoms or death-not mistakenly diagnosing cancer where none exists.

The word “cancer” is so powerful that perhaps the profession should consider a different name for certain very low-risk lesions. Some patients may find it difficult to accept active surveillance as a response to “cancer,” however carefully their doctors explain that the disease is unlikely to threaten their lives. Changing the terminology would not eliminate the need for appropriate monitoring, but it might reduce the pressure to treat a condition whose treatment could do more harm than the condition itself.

This possibility is already being debated. The new ACS guideline identifies renaming Grade Group 1 cancer as a subject for further research. Whether removing the label would improve decisions without compromising outcomes remains unsettled.

MRI and active surveillance reduce some of the harms of screening. Randomized evidence shows that MRI-directed biopsy can substantially reduce detection of clinically insignificant cancers. Carefully selected surveillance cohorts have favorable long-term outcomes. But neither approach abolishes the burdens of diagnosis, and neither proves that more intensive screening produces a favorable overall balance in every group. Surveillance itself entails continuing examinations, tests, and sometimes repeated biopsies.

Active surveillance should also be distinguished from watchful waiting. Surveillance uses scheduled assessments to identify changes that might justify treatment with curative intent. Watchful waiting generally focuses on treating symptoms if they develop and is often appropriate when limited life expectancy makes curative treatment unlikely to provide benefit.

Primary-care doctors should therefore treat the new guidelines as a reason to improve decisions, not simply increase the number of tests. Their strengths are a clearer recognition of mortality benefit, attention to men at greater risk, and explicit efforts to avoid unnecessary biopsy and treatment. Their weakness is that a precise schedule can convey more certainty than the comparative evidence supports. A recommendation is a policy judgment informed by science; it is not itself an experimental result.

A conservative, guideline-supported approach for an average-risk man is to follow the current USPSTF framework: discuss screening at ages 55-69, test only after an informed choice, and discontinue screening at 70. For those choosing testing, a two-year interval is a reasonable restrained practice, although it is not a specific USPSTF mandate. Screening should also stop earlier when life expectancy is under ten years or when finding cancer would not lead to an intervention the patient could benefit from and would accept. An informed decision to decline screening is legitimate.

A more aggressive approach-starting at 50 in average-risk men, at 45 in higher-risk men, testing selected men annually, or continuing through 74-can also be reasonable. It should require an identifiable rationale: increased risk, sufficient life expectancy, a patient who values the possible benefit, and access to careful follow-up that limits unnecessary treatment. It should not arise merely because PSA can be added to a laboratory panel.

The doctor should explain that screening may reduce the chance of metastatic prostate cancer or death from it, but that the absolute benefit is small for many men and usually delayed. The additional benefit of starting earlier or testing more frequently is less certain. False alarms and the discovery of cancers that would never have caused symptoms or shortened life are possible. An abnormal result does not automatically require biopsy, and a cancer diagnosis does not automatically require treatment.

A cautious doctor need not reject the new ACS recommendations, and a more interventionist doctor need not pretend that their every detail has been proved. Both should explain the uncertainty, respect the patient’s preferences, and agree in advance on when testing will stop. The obligation is to help the patient make a choice he understands, including the possibility that doing less may serve him better.

0

Categories

Filed Under:

Uncategorized

Comments

Loading